Portfolio with a primary focus on Digital Health & TechBio – examples investments include Abterra Bio, BlueNalu, Elicio Therapeutics (Exited to Nasdaq: ELTX), Iridia, Pleno, and Syntrillo.Served in advisory, mentorship and leadership roles at NuFund Venture Group, the San Diego Angel Conference, and the Nex Cubed Digital Health Accelerator

Austin continues transforming into the next innovation powerhouse. In this podcast we explore how Central Texas is growing…The people and companies, the industries and infrastructure, the macro and micro trends that come together to create the future of Austin.We want to answer one basic question… What’s Next Austin?

Led strategic planning, product management, and business development functions for direct-to-consumer microbiome solutions divisionDeveloped and launched version 2 of Gut microbiome test with updated bioinformatics pipeline Developed first women’s health test that included microbiome test with HPV and STI diagnostic Relaunched consumer brand as Kean Health with new marketing assets and strategy, product portfolio, and partnerships

Drove commercial strategic planning process enabling revenue growth from $3B to $4B, included deliverables such as Board of Directors presentations, multiyear budgets, and operating plans. Led software strategy core team that developed product, partnership, marketing, and commercial programs doubling revenue. Launched an internal podcast to increase sales communication and effectiveness achieving 25% penetration within 5 episodes.Designed the expansion strategy of the Illumina Accelerator into Illumina for Startups. Coached Illumina Accelerator portfolio companies on strategy, fundraising, and communication leading to increased engagement with angel and seed investors

Managed worldwide strategy for HealthSight enabling launch of first two solutions - Inventory Optimization and Diversion ManagementCreated a funnel of new solution concepts through identification of unmet customer and market needs, characterizing market size, and building initial concepts for testing

Directed the strategic planning process, set the strategy, financial objectives for a $2B business. Led the intelligence team for a $15B global market that monitored key marketplace events (M&A, partnerships, new technologies, company reporting, and new regulations), conducted competitive analysis (SWOT, workshops), and built a repository of market knowledge. Filled a product portfolio gap with a 10-year IV fluid US distribution partnership with Fresenius.

Rebuilt market intelligence function for an $8B global market building tools such as market trend reports, market size dashboards, and competitive insight tracking.Executed strategic fit assessment, commercial due diligence, and financial valuation leading to a $100M investment in Caesarea Medical Electronics.•Conceptualized, initiated, and closed a commercialization and development partnership with Edwards Lifesciences forecasted for double digit millions in revenue.

Led the market intelligence function for the $1B chronic kidney disease franchise SensiparConducted the global marketing effectiveness project across all tactics and campaigns to inform prioritization and budgeting tradeoffs

Consulted with growth life science companies (<$100M revenue) on strategic and partnership questions and with large biopharma clients on marketing strategy and insights. Clients Included: Amgen, CareDx (formerly XDx), Eisai, Cerimon Pharmaceuticals, Cadence Pharmaceuticals, Nodality, Pricespective, & the Aequitas Group

Created business plan, conducted financial valuation and term sheet analyses for a $50M development partnership with Edwards Lifesciences.